Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.61 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24937350 | 0.82 | LMNA (0.48) | L3MBTL1TSHRMAPK1TDP1LMNA | |
| SCHEMBL38674 | 0.81 | L3MBTL1 (0.68) | L3MBTL1MMP2TSHRLMNAFFAR1 | |
| SCHEMBL7425169 | 0.79 | ALOX15 (0.65) | TSHRLMNAFFAR1 | |
| SCHEMBL10877978 | 0.79 | L3MBTL1 (0.66) | L3MBTL1MMP2TSHRLMNAFFAR1 | |
| SCHEMBL30954573 | 0.78 | CHRNB2 (0.56) | L3MBTL1 | |
| Quinoxaline SCHEMBL6035457 | 0.78 | L3MBTL1 (0.54) | L3MBTL1MMP2TSHRMAPK1LMNA | |
| SCHEMBL15429528 | 0.78 | CHRNB2 (0.56) | L3MBTL1 | |
| SCHEMBL525095 | 0.78 | CYP2D6 (0.56) | L3MBTL1TSHRMAPK1LMNANPC1 | |
| SCHEMBL2468006 | 0.78 | L3MBTL1 (0.69) | L3MBTL1MMP2TSHRLMNAFFAR1 | |
| SCHEMBL28539082 | 0.78 | L3MBTL1 (0.63) | L3MBTL1MMP2TSHRLMNAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240245675-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. | 2024-07-25 | — | — | US | disclosed |
| EP-4377298-A1 | PROTEIN SECRETION INHIBITORS | Gate Bioscience, Inc. (US) | 2024-06-05 | — | — | EP | disclosed |
| CN-117999256-A | Protein secretion inhibitor | 分子门生物科技公司 | 2024-05-07 | — | — | CN | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| WO-2023010051-A1 | PROTEIN SECRETION INHIBITORS | GATE BIOSCIENCE, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240245675-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | L3MBTL1 3944/4885MMP2 1510/4885TSHR 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.